A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

被引：5

作者：

Park, Cheol-Kyu ^{[1
]}

Jeon, Nakyung ^{[2
,3
]}

Park, Hwa-Kyung ^{[1
]}

Oh, Hyung-Joo ^{[1
]}

Kim, Young-Chul ^{[1
]}

Jeon, Ha-Lim ^{[4
]}

Kim, Yong-Hyub ^{[5
]}

Ahn, Sung-Ja ^{[5
]}

Oh, In-Jae ^{[1
]}

机构：

[1] Chonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Med Sch, Dept Internal Med, Hwasun 58128, South Korea

[2] Pusan Natl Univ, Coll Pharm, Pusan 46241, South Korea

[3] Pusan Natl Univ, Res Inst Drug Dev, Pusan 46241, South Korea

[4] Jeonbuk Natl Univ, Coll Pharm, Jeonju 54896, South Korea

[5] Chonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Med Sch, Dept Radiat Oncol, Hwasun 58128, South Korea

来源：

CANCERS | 2023年 / 15卷 / 05期

基金：

新加坡国家研究基金会;

关键词：

real-world study; concurrent chemoradiotherapy; durvalumab; non-small cell lung cancer; CONSOLIDATION DURVALUMAB; THERAPY; CHEMORADIATION; NSCLC;

D O I：

10.3390/cancers15051606

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary The PACIFIC trial demonstrated the survival benefits of durvalumab consolidation (DC) in patients with unresectable stage III non-small cell lung cancer (NSCLC). In this retrospective cohort study, using a propensity score-matched analysis, we investigated the effectiveness of DC after concurrent chemoradiotherapy (CCRT) and compared DC after CCRT with a historical control in this regard. DC was tolerable and consistently associated with survival benefits (compared with a lack of DC) in real-world contexts. This study suggested that the outcomes of the PACIFIC trial could be successfully translated into real practice and that DC after CCRT could be established as a new standard of care for stage III NSCLC. This study aimed to add real-world evidence to the literature regarding the effectiveness and safety of durvalumab consolidation (DC) after concurrent chemoradiotherapy (CCRT) in the treatment of unresectable stage III non-small cell lung cancer (NSCLC). Using a hospital-based NSCLC patient registry and propensity score matching in a 2:1 ratio, we conducted a retrospective cohort study of patients with unresectable stage III NSCLC who completed CCRT with and without DC. The co-primary endpoints were 2-year progression-free survival and overall survival. For the safety evaluation, we evaluated the risk of any adverse events requiring systemic antibiotics or steroids. Of 386 eligible patients, 222 patients-including 74 in the DC group-were included in the analysis after propensity score matching. Compared with CCRT alone, CCRT with DC was associated with increased progression-free survival (median: 13.3 vs. 7.6 months, hazard ratio[HR]: 0.63, 95% confidence interval[CI]: 0.42-0.96) and overall survival (HR: 0.47, 95% CI: 0.27-0.82) without an increased risk of adverse events requiring systemic antibiotics or steroids. While there were differences in patient characteristics between the present real-world study and the pivotal randomized controlled trial, we demonstrated significant survival benefits and tolerable safety with DC after the completion of CCRT.

引用

页数：14

共 38 条

[21] Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population [J].